Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: Has it a diagnostic role?

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1206-1211

  Kara, B ^a   Doran, F ^a   Kara, I O ^a   Akkiz, H ^a   Sandikci, M ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; HEMATOXYLIN; MONOCLONAL ANTIBODY; PARAFFIN; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CELL PROLIFERATION; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DYSPLASIA; FEMALE; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STAINING; TISSUE SECTION;

ADULT; AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; EARLY DIAGNOSIS; FEMALE; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTO-ONCOGENE PROTEINS C-KIT; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL;

EID: 47149089624     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01675.x     Document Type: Article

References (28)

1. Barazani Y, Hiatt JR, Tong MJ. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007 31 : 1243 8.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 76.
3. Feitelson MA, Lee J. Hepatitis B virus integration, fragile sites and hepatocarcinogenesis. Cancer Lett 2007 252 : 157 70.
4. Lupberger J, Hildt E. Hepatitis B virus induced oncogenesis. World J Gastroenterol 2007 13 : 74 81.
5. Koskinas J, Petraki K, Kavantzas N et al. Hepativ expressionof the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma. J Viral Hepat 2005 12 : 635 41.
6. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II Study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 24 : 4293 300.
7. Rougier P, Mitry E, Barbare JC et al. Hepatocellular carcinoma (HCC): an update. Semin Oncol 2007 34 : 12 20.
8. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006 66 : 11851 8.
9. Liovet J, Ricci S, Mazzaferro P et al. Sorafenib improves survival in advanced HCC: Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007 25, ASCO Annual Meeting Proceedings Part I No.18S.
10. Konig A, Corbacioglu S, Ballmaier M et al. Downregulation of c-kit expression in human endothelial cells by inflammatory stimuli. Blood 1997 90 : 148 55.
11. Ashman LK. The biology of stem cell factor and its receptor c-kit. Int J Biochem Cell Biol 1999 31 : 1037 51.
12. Wiedmann MW, Caca K. Moleculerly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005 5 : 171 93.
13. Lee ES, Han EM, Kim YS et al. Occurrence of c-kit+ tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol 2005 124 : 31 6.
14. Baumann U, Crosby HA, Ramani P et al. Expression of stem cell factor c-kit in normal and diseased pediatric liver: identification of a human hepatic progenitor cell? Hepatology 1999 30 : 112 7.
15. Reber L, Silva CAD, Frossard N. Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol 2006 533 : 327 40.
16. Knodell RG, Ihsak KG, Black WC et al. Formulation and application of a numerical scoring system for assesing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 5.
17. El Desmet VJ, Gerber M, Hoofnagle JH et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 20.
18. Eleazar JA, Memeo L, Jhang SJ et al. Progenitor cell expansion: an important source of hepatocyte regeneration in chronic hepatitis. J Hepatol 2004 41 : 983 91.
19. Hwang SJ, Tong MJ, Lai PP et al. Evaluation of hepatitis B and C viral markers: clinical significance in Asian and Caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol 1996 11 : 949 54.
20. Kubicka S, Rudolph KL, Hanke M et al. Hepatocellular carcinoma in Germany: aretrospective epidemiological study from a low endemic area. Liver 2000 20 : 312 8.
21. Raptis I, Koskinas J, Emmanouil T et al. Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations. J Viral Hepat 2003 10 : 450 4.
22. Yamamato T, Uenishi T, Ogawa M et al. Immunohistologic attempt to find carcinogenesis from hepatic progenitor cell in hepatocellular carcinoma. Dig Surg 2005 22 : 364 70.
23. Campbell JS, Hughes SD, Gilbertson DG et al. Platelet derived growth factor C induces liver fibrosis, steatosis and HCC. Proc Natl Acad Sci USA 2005 102 : 3389 94.
24. Potti A, Ganti AK, Tendulkar K et al. HER-2/neu and CD117 (C-kit) over expression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003 23 (3B 2671 4.
25. Eckel F, von Delius S, Mayr M et al. Phamacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005 69 : 363 71.
26. Becker G, Schmidtt-Graeff A, Ertelt V. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol 2007 19 : 204 8.
27. Ramodori G, Fuzesi L, Grabbe E et al. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004 15 : 405 9.
28. Chung CY, Yeh KT, Hsu NC et al. Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 2005 217 : 231 6.